Summary of Q3 2025 Earnings Call for Pediatrix Medical Group, Inc.

1Key Financial Results and Metrics

Adjusted EBITDA: $87 million, exceeding expectations.

Consolidated Revenue: Decreased by approximately $54 million due to portfolio restructuring but was offset by strong same-unit growth of 8% and pricing up 7.5%.

Operating Cash Flow: Increased to $138 million from $96 million year-over-year, driven by higher earnings and improved cash flow from accounts receivable (AR).

Share Repurchases: 1.2 million shares bought back in the quarter, totaling 1.7 million shares year-to-date.

Cash Position: Ended the quarter with $340 million in cash and net debt of just over $260 million, reflecting a net leverage of under 1x based on adjusted EBITDA outlook.

2Strategic Updates and Business Highlights

Portfolio Restructuring: Successfully executed, leading to improved operational performance and focus on core areas such as pediatric surgery, neurology, and cardiac intensive care.

Research and Innovation: Pediatrix maintains a significant clinical footprint with over 1,300 physicians and 1,170 advanced practice providers. They are a leader in neonatology research with 1,395 peer-reviewed publications.

Technology Leadership: Introduction of the proprietary BabySteps system aimed at enhancing clinical decision-making and improving outcomes for high-risk NICU patients.

Acquisition Activity: Completed an acquisition of several neonatology, MFM, and OB hospitalist practices, reinforcing their market position.

3Forward Guidance and Outlook

Full-Year Adjusted EBITDA Guidance: Wider range of $270 million to $290 million due to practice bonus variability.

Seasonality: Anticipated normal seasonality in Q4 with no expected shifts, although some variability may arise from ongoing initiatives.

4Bad News, Challenges, or Points of Concern

Revenue Decline: The decrease in consolidated revenue due to restructuring raises concerns about the impact on future growth.

Expense Increases: General and administrative expenses rose slightly due to increased incentive compensation, which could pressure margins.

Market Headwinds: The company acknowledged significant healthcare headwinds that could affect operations and financial performance moving forward.

5Notable Q&A Insights

Capital Deployment: Management is cautious but open to aggressive share repurchases and exploring internal and external growth opportunities.

Competitive Landscape: The restructuring has not negatively impacted the company’s attractiveness to new practices; instead, it has enhanced focus and operational efficiency.

Pricing Dynamics: Strong pricing was attributed to improved RCM collections, increased acuity, and favorable payer mix, though these factors are variable and may not sustain.

Exchange Subsidies: Uncertainty remains regarding the impact of enhanced subsidies on exchange plans, with management hopeful for continued benefits. Overall, Pediatrix Medical Group reported a strong quarter with solid operational metrics despite challenges from restructuring and market conditions. The company remains focused on strategic growth and innovation while navigating potential headwinds in the healthcare landscape.